IP Verse

Pharmaceutical Composition Comprising Hmg-Coa Reductase Inhibitors And Fenofibrate

Patent No. EP3833335 (titled "Pharmaceutical Composition Comprising Hmg-Coa Reductase Inhibitors And Fenofibrate") was filed by Intas Pharmaceuticals on Jul 30, 2020. The application was issued on Aug 31, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
VIATRIS HEALTHCARE LDAJun 5, 2024ELKINGTON AND FIFE
ELKINGTON AND FIFEMay 30, 2023ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3833335

INTAS PHARMACEUTICALS
Application Number
EP20764155A
Filing Date
Jul 30, 2020
Status
Granted And Under Opposition
Jul 29, 2022
Publication Date
Aug 31, 2022
External Links
Slate, Register , Google Patents